Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 17, Issue 7, 2007, Pages 493-498

  Manini, Rita ^a   Forlani, Gabriele ^a   Moscatiello, Simona ^a   Zannoni, Chiara ^a   Marzocchi, Rebecca ^a   Marchesini, Giulio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Glargine; Hypoglycemia; Insulin; Quality of life; Type 1 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; GLYCOSYLATED HEMOGLOBIN; INSULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COST OF ILLNESS; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

ADULT; AGED; COST OF ILLNESS; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 34547485915     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2006.07.001     Document Type: Article

References (22)

1. Hanestad B.R., and Albrektsen G. Quality of life, perceived difficulties in adherence to a diabetes regimen, and blood glucose control. Diabet Med 8 (1991) 759-764
2. Jacobson A.M. Quality of life in patients with diabetes mellitus. Semin Clin Neuropsychiatry 2 (1997) 82-93
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
4. Beaser R.S., Garbus S.B., and Jacobson A.M. Diabetes mellitus. In: Spilker B. (Ed). Quality of life in clinical trials (1996), Lippincott-Raven, Philadelphia 983-992
5. Patrick D.L., and Deyo R.A. Generic and disease-specific measures in assessing health status and quality of life. Med Care 27 (1989) S217-S232
6. Bardsley M.J., Astell S., McCallum A., and Home P.D. The performance of three measures of health status in an outpatient diabetes population. Diabet Med 10 (1993) 619-626
7. Parkerson Jr. G.R., Connis R.T., Broadhead W.E., Patrick D.L., Taylor T.R., and Tse C.K. Disease-specific versus generic measurement of health-related quality of life in insulin-dependent diabetic patients. Med Care 31 (1993) 629-639
8. Raskin P., Klaff L., Bergenstal R., Halle J.P., Donley D., and Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 (2000) 1666-1671
9. Murphy N.P., Keane S.M., Ong K.K., Ford-Adams M., Edge J.A., Acerini C.L., et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 26 (2003) 799-804
10. Fischer J.S., McLaughlin T., Loza L., Beauchamp R., Schwartz S., and Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 20 (2004) 1703-1710
11. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Report No. WHO/NCD/NCS/99.2 (1999), World Health Organization, Geneva p. 31-3
12. Forlani G., Zannoni C., Tarrini G., Melchionda N., and Marchesini G. An empowerment-based educational program improves psychological well-being and health-related quality of life in type 1 diabetes. J Endocrinol Invest 29 (2006) 405-412
13. Mannucci E., Ricca V., Bardini G., and Rotella C.M. Well-being enquiry for diabetics: a new measure of diabetes-related quality of life. Diab Nutr Metab 9 (1996) 89-102
14. Bott U., Muhlhauser I., Overmann H., and Berger M. Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care 21 (1998) 757-769
15. The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the diabetes control and complications trial (DCCT). Diabetes Care 11 (1988) 725-732
16. Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca T.E., and Wilson C.A. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23 (2000) 639-643
17. Rossetti P., Pampanelli S., Fanelli C., Porcellati F., Costa E., Torlone E., et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26 (2003) 1490-1496
18. Fulcher G.R., Gilbert R.E., and Yue D.K. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35 (2005) 536-542
19. Kotsanos J.G., Vignati L., Huster W., Andrejasich C., Boggs M.B., Jacobson A.M., et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 20 (1997) 948-958
20. Bott U., Ebrahim S., Hirschberger S., and Skovlund S.E. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med 20 (2003) 626-634
21. Watkins K., and Connell C.M. Measurement of health-related QOL in diabetes mellitus. Pharmacoeconomics 22 (2004) 1109-1126
22. Garratt A.M., Schmidt L., and Fitzpatrick R. Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med 19 (2002) 1-11